ClinicalTrials.gg
CompletedNCT01329029REACTUpdated Dec 13, 2016Results posted

Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Combinations of Long-acting β2-agonists (LABA) and Inhaled Glucocorticosteroid (ICS)

A Phase 4 interventional study of Roflumilast and Placebo in Chronic Obstructive Pulmonary Disease, sponsored by AstraZeneca. Completed at 180 sites in 21 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2016-12-13.

Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,945
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive — 1 open to participants now, 1 under way, none of them phase 3. Roflumilast · Pulmonary Disease, Chronic Obstructive.

Enrollment
2nd of 32
1,945 · median 154
Started
2011
with 4 others
Phase 4
8 of 32
1 open now
Registered
13th of 32
by date
Lead sponsor
18 of 32
AstraZeneca

Among the 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive, this one is the 2nd largest by enrollment, is one of 5 that started in 2011, is one of 8 in phase 4, and was the 13th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

1 of the 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive is open now. Recruiting first, the newest first:

About roflumilast

Roflumilast: first FDA approval 2011 (DALIRESP), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

The objective of the REACT trial is to investigate the effect of roflumilast 500 μg tablets once daily versus placebo on exacerbation rate and pulmonary function in COPD patients who are concomitantly treated with a fixed combination of long-acting β2-agonists (LABA) and inhaled glucocorticosteroids (ICS). In addition, data on safety and tolerability of roflumilast will be obtained. An additional objective is to further characterize the population pharmacokinetic profile of roflumilast and roflumilast N oxide and to further characterize their pharmacokinetics/pharmacodynamics (PK/PD) relationship in terms of efficacy and relevant safety aspects.

Patients to be included are required to have severe COPD associated with chronic bronchitis and a history of frequent exacerbations and must be concomitantly treated with a fixed combination of LABA and ICS. Two parallel treatment arms (roflumilast 500 μg once daily and placebo) are included.

Read the detailed description

The drug tested in this study is called Roflumilast. Roflumilast is being developed to treat people who have chronic obstructive pulmonary disease (COPD). This study investigated the effect of roflumilast 500 μg tablets once daily versus placebo on exacerbation rate, pulmonary function, and major adverse cardiovascular events (MACE) in COPD patients who were concomitantly treated with a fixed combination of long-acting beta-agonists (LABA) and inhaled glucocorticosteroids.

The study was targeted to enroll approximately 1934 patients. Participants were randomly assigned (by chance, like flipping a coin) to one of the two treatment groups-which remained undisclosed to the patient and study doctor during the study (unless there was an urgent medical need):

  • Roflumilast 500 μg once daily
  • Placebo (dummy inactive pill) - this was a tablet that looked like the study drug but had no active ingredient

Trial treatment was taken in the morning by mouth after breakfast with some water.

The trial consisted of the following periods:

  • Single-blind baseline period (4 weeks) during which all patients received placebo.
  • Double-blind treatment period (52 weeks) during which patients received either roflumilast or matching placebo.
  • Safety follow-up (30 days after end of treatment (Vend) or premature discontinuation date) in case of ongoing Adverse Events at Vend, if necessary.
  • Follow-up visit 12 weeks after end of treatment, at Week 64 (VFU), only for patients who completed the trial as scheduled.

This multi-center trial was conducted worldwide. The overall time to participate in this study was up to 64 weeks. Participants made multiple visits to the clinic which included a follow-up visit at week 64.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease

Keywords

  • COPD
  • Roflumilast
  • Daxas
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Giving written
  • History of (according to GOLD 2009) for at least 12 months prior to baseline Visit V0 associated with chronic productive cough for 3 months in each of the 2 years prior to baseline visit (with other causes of productive cough excluded)
  • Age ≥ 40 years
  • Forced expiratory volume after one second ()/forced vital capacity (FVC) ratio (post-bronchodilator) \< 70%
  • FEV1 (post-bronchodilator) ≤ 50% of predicted
  • At least two documented moderate or severe COPD exacerbations within one year prior to baseline visit
  • Patients must be pre-treated with LABA and ICS for at least 12 months before baseline Visit V0. Up to 3 months before baseline Visit V0 free or fixed combinations of LABA and ICS are allowed, including changes in dose, active substances, and brands. In the last 3 months before baseline Visit V0 patients must be pre-treated with fixed combinations of LABA and ICS at a constant dose (maximum approved dosage strength of the combination).
  • Former smoker (defined as smoking cessation at least one year ago) or current smoker both with a smoking history of at least 20 pack years

Main Exclusion Criteria:

  • Exacerbations not resolved at first baseline visit
  • Diagnosis of asthma and/or other relevant lung disease
  • Known alpha-1-antitrypsin deficiency
  • Other protocol-defined exclusion criteria may apply
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,945 participants (actual)

Study arms

  • Active comparator
    Roflumilast

    concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid

    Drug: Roflumilast

  • Placebo comparator
    Placebo

    concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid

    Drug: Placebo

Interventions

  • 500 µg, once daily

  • DrugPlacebo

    once daily

06

What researchers measure

Primary outcomes

  1. Rate of Moderate or Severe COPD Exacerbations Per Patient Per Year

    A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient's baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management. COPD exacerbations were categorized as follows: Severe=Requiring hospitalization and/or leading to death; Moderate=Requiring oral or parenteral glucocorticosteroid therapy. The defined number of days a patient was in the trial was divided by 365.25, in order to express the duration as a fraction of 1 year.

    Time frame: 52 weeks

Secondary outcomes

  1. Change From Baseline in Post-Bronchodilator Forced Expiratory Volume in the First Second (FEV1)

    Pulmonary function testing was performed using centralised spirometry. FEV1 is the maximum amount of air that can be forcefully exhaled in one second. Least-squares means is from Analysis of Covariance (ANCOVA) including treatment by time interaction. A positive change from Baseline indicates improvement.

    Time frame: Baseline and Week 52

  2. Rate of Severe COPD Exacerbations Per Patient Per Year

    A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient's baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management. Severe COPD exacerbations were categorized as requiring hospitalization and/or leading to death. The defined number of days a patient was in the trial was divided by 365.25, in order to express the duration as a fraction of 1 year.

    Time frame: 52 weeks

  3. Rate of COPD Exacerbations Per Patient Per Year All Categories

    A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient's baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management. COPD exacerbations were categorized as follows: Severe=Requiring hospitalization and/or leading to death; Moderate=Requiring oral or parenteral glucocorticosteroid therapy. The defined number of days a patient was in the trial was divided by 365.25, in order to express the duration as a fraction of 1 year.

    Time frame: 52 weeks

  4. Percentage of Participants Experiencing at Least 1 COPD Exacerbation

    A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient's baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management.

    Time frame: 52 weeks

  5. Time to First COPD Exacerbation All Categories

    Time to event was calculated as date of onset of event - date of first intake of double-blind study drug + 1 day for all events: mild, moderate or severe. A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient's baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management.

    Time frame: 52 Weeks

  6. Time to Second Moderate or Severe COPD Exacerbation

    Time to event was calculated as date of onset of event - date of first intake of double-blind study drug + 1 day for events: moderate or severe. A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient's baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management. COPD exacerbations were categorized as Severe: Requiring hospitalization and/or leading to death; Moderate: Requiring oral or parenteral glucocorticosteroid therapy.

    Time frame: 52 Weeks (some participants extended treatment beyond 52 Weeks and are included in the analysis)

  7. Time to Third Moderate or Severe COPD Exacerbation

    Time to event was calculated as date of onset of event - date of first intake of double-blind study drug + 1 day for events: moderate or severe. A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient's baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management. COPD exacerbations were categorized as Severe: Requiring hospitalization and/or leading to death; Moderate: Requiring oral or parenteral glucocorticosteroid therapy.

    Time frame: 52 Weeks

  8. Number of Patients Needed to Treat to Avoid 1 Moderate or Severe COPD Exacerbation Derived From Exacerbation Per Patient Per Year

    The number needed to treat (NNT) analysis is a simple, concise method to quantify directly the benefits that alternative treatment options have on disease outcomes in terms of the number of patients who need to be treated before a benefit is observed. Risk reduction: Rate(Placebo)- Rate (Roflumilast 500 μg), Number needed to treat for benefit (NNTB): 1/(Risk reduction). A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient's baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management. COPD exacerbations were categorized as Severe: Requiring hospitalization and/or leading to death; Moderate: Requiring oral or parenteral glucocorticosteroid therapy.

    Time frame: 52 Weeks

  9. Number of Moderate or Severe COPD Exacerbation Days

    A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient's baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management. The number of exacerbation days per patient is the sum of durations (stop date of exacerbation - start date of exacerbation + 1) of all exacerbations within the category.

    Time frame: 52 Weeks

  10. Duration of Moderate or Severe COPD Exacerbations Per Participant

    A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient's baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management.

    Time frame: 52 Weeks

  11. Change From Baseline in Post-Bronchodilator Forced Vital Capacity (FVC)

    Forced vital capacity is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Least-squares means was from ANCOVA including treatment by time interaction. A positive change from Baseline indicates improvement.

    Time frame: 52 weeks

  12. Change From Baseline in Post-Bronchodilator Forced Expiratory Flow at 25% to 75% of Vital Capacity (FEF25-75%)

    Forced expiratory flow 25-75% (FEF25-75%) is the flow (or speed) of air coming out of the lung during the middle half of a forced expiration. Pulmonary function testing was performed using centralized spirometry. Least-squares means was from ANCOVA including treatment by time interaction. A positive change from Baseline indicates improvement.

    Time frame: 52 weeks

  13. Change From Baseline in Post-Bronchodilator Forced Expiratory Volume in the First 6 Seconds (FEV6)

    FEV6 is the amount of air which can be forcibly exhaled from the lungs in the first six seconds of a forced exhalation. Pulmonary function testing was performed using centralized spirometry. A positive change from Baseline indicates improvement.

    Time frame: 52 weeks

  14. Change From Baseline in Post-Bronchodilator FEV1/FVC

    The FEV1/FVC ratio represents the percentage of vital capacity expelled from the lungs during the first second of a forced exhalation. Pulmonary function testing was performed using centralized spirometry. A positive change from Baseline indicates improvement.

    Time frame: 52 weeks

  15. Change From Baseline in Use of Rescue Medication From Daily Diary

    Salbutamol metered dose inhaler was available as rescue medication during the study. The participant recorded the use of rescue medication in a daily diary. A negative change from Baseline indicates an improvement.

    Time frame: Baseline and Week 52

  16. Change From Baseline in COPD Symptom Score From Daily Diary

    Participants recorded COPD symptoms cough and sputum production in a daily diary. Cough was assessed using a 4-point scale where 0=No cough to 3=severe cough and sputum was assessed using a 4-point scale where 0=no sputum production to 3=severe sputum production. Least-squares means from ANCOVA including treatment by time interaction. A negative change from Baseline indicates improvement. Total symptom score is the sum of cough and sputum scores, ranging from 0 (best possible outcome) to 6 (worst possible outcome).

    Time frame: 52 weeks

  17. Percentage of Symptom-Free Days

    Symptoms of COPD (cough, sputum) were recorded in a daily diary. The percentage of days without symptoms is reported.

    Time frame: 52 Weeks

  18. Percentage of Rescue Medication-Free Days

    Participants recorded their use of rescue medication in a daily diary. The percentage of days without rescue medication use.

    Time frame: 52 Weeks

  19. Change From Baseline in COPD Assessment Test (CAT) Total Score

    Participants completed the CAT questionnaire at Baseline and after 52 Weeks of Treatment. The CAT questionnaire measures the impact of COPD on wellbeing and daily life. Participants answer 8 questions on a scale from 0 (best) to 5 (worst). The total score ranges from 0 to 40 with higher scores indicating more impact. A negative change from Baseline indicates improvement. Least-squares means from ANCOVA including treatment by time interaction.

    Time frame: Baseline and Week 52

  20. Percentage of Participants With Improvement in CAT

    Participants completed the CAT questionnaire at Baseline and after 52 Weeks of treatment. The CAT questionnaire measures the impact of COPD on wellbeing and daily life. Participants answer 8 questions on a scale from 0 (best) to 5 (worst). The total score ranges from 0 to 40 with higher scores indicating more impact. Improvement was defined as a CAT Total Score reduction from Baseline \> 1.6.

    Time frame: Baseline and Week 52

  21. Time to Mortality Due to Any Reason During the Treatment Period Score

    Time to event will be calculated as date of onset of event - date of first intake of double-blind study drug + 1 day.

    Time frame: 52 Weeks (some participants extended treatment beyond 52 Weeks and are included in the analysis)

  22. Time to Mortality Due to COPD Exacerbation During the Treatment Period

    Time to event will be calculated as date of onset of event - date of first intake of double-blind study drug + 1 day.

    Time frame: 52 Weeks

  23. Time to Withdrawal During the Treatment Period

    Time to event will be calculated as date of onset of event - date of first intake of double-blind study drug + 1 day.

    Time frame: 52 Weeks (some participants extended treatment beyond 52 Weeks and are included in the analysis)

  24. Time to Withdrawal Due to COPD Exacerbation During the Treatment Period

    Time to event will be calculated as date of onset of event - date of first intake of double-blind study drug + 1 day.

    Time frame: 52 Weeks (some participants extended treatment beyond 52 Weeks and are included in the analysis)

  25. Percentage of Participants With Major Adverse Cardiovascular Event (MACE) During the Treatment Period

    Composite MACE is a combined endpoint (cardiovascular death \[including death due to undetermined cause\], nonfatal myocardial infarction, and nonfatal stroke).

    Time frame: 52 Weeks

  26. Time to First Major Adverse Cardiovascular Event (MACE) During the Treatment Period

    Composite MACE is a combined endpoint(cardiovascular death \[including death due to undetermined cause\], nonfatal myocardial infarction, and nonfatal stroke). Time to event was calculated as date of onset of event - date of first intake of double-blind study drug + 1 day.

    Time frame: 52 Weeks (some participants extended treatment beyond 52 Weeks and are included in the analysis)

  27. Percentage of Participant With All-Cause Hospitalisation During the Treatment Period

    Percentage of patients with at least one hospital admission due to any cause.

    Time frame: 52 Weeks

  28. Time to First Hospitalisation Due to Any Cause During the Treatment Period

    Time to event will be calculated as date of onset of event - date of first intake of double-blind study drug + 1 day.

    Time frame: 52 Weeks (some participants extended treatment beyond 52 Weeks and are included in the analysis)

  29. Time to Trial Withdrawal Due to an Adverse Event

    Time to event will be calculated as date of onset of event - date of first intake of double-blind study drug + 1 day.

    Time frame: 52 Weeks (some participants extended treatment beyond 52 Weeks and are included in the analysis)

  30. Percentage of Participants Who Experienced at Least 1 Treatment Emergent Adverse Event (TEAE)

    An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.

    Time frame: 52 Weeks

  31. Change From Baseline in Body Weight

    Least Square Means was from an ANCOVA model including Last Observation Carried Forward (LOCF).

    Time frame: Baseline and Week 52

  32. Change From Baseline in Body Mass Index (BMI)

    Body mass index (BMI) is a measure of body fat based on height and weight. Least Square Means was from an ANCOVA model including LOCF.

    Time frame: Baseline and Week 52

07

Results

Posted Oct 29, 2015

Participant flow

Participants took part in the study at 203 investigative sites in Australia, Austria, Belgium, Brazil, Canada, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Korea (Republic of), Netherlands, Poland, Russia, Slovak Republic, South Africa, Spain, Turkey and United Kingdom from 28 May 2011 to 27 May 2014.

Participant flow — Overall Study
MilestoneRoflumilast 500 µgPlacebo
Started973972
Full analysis set (fas)969966
Safety population968967
Completed704780
Not completed269192
Withdrew: Withdrawal by subject11787
Withdrew: Adverse event8229
Withdrew: Death1619
Withdrew: Other1420
Withdrew: Copd exacerbation1118
Withdrew: Physician decision1613
Withdrew: Lost to follow-up85
Withdrew: Met pre-defined discontinuation criteria51

Outcome measures

PrimaryRate of Moderate or Severe COPD Exacerbations Per Patient Per Year

A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient's baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management. COPD exacerbations were categorized as follows: Severe=Requiring hospitalization and/or leading to death; Moderate=Requiring oral or parenteral glucocorticosteroid therapy. The defined number of days a patient was in the trial was divided by 365.25, in order to express the duration as a fraction of 1 year.

Time frame:
52 weeks
Reported as:
Mean · exacerbations per patient per year
Rate of Moderate or Severe COPD Exacerbations Per Patient Per Year
exacerbations per patient per yearRoflumilast 500 µgPlacebo
Rate of Moderate or Severe COPD Exacerbations Per Patient Per Year0.805 (0.724 to 0.895)0.927 (0.843 to 1.020)
Statistical analysis
  • Roflumilast 500 µg vs Placebo · Generalized Linear Regression · p = 0.0529 (Level of significance: 5% 2-sided) · Rate ratio: 0.868 · 95% CI 0.753 to 1.002A rate ratio of \< 1 represents a favourable outcome for the test treatment.
SecondaryChange From Baseline in Post-Bronchodilator Forced Expiratory Volume in the First Second (FEV1)

Pulmonary function testing was performed using centralised spirometry. FEV1 is the maximum amount of air that can be forcefully exhaled in one second. Least-squares means is from Analysis of Covariance (ANCOVA) including treatment by time interaction. A positive change from Baseline indicates improvement.

Time frame:
Baseline and Week 52
Reported as:
Least squares mean · liters
Change From Baseline in Post-Bronchodilator Forced Expiratory Volume in the First Second (FEV1)
litersRoflumilast 500 µgPlacebo
Change From Baseline in Post-Bronchodilator Forced Expiratory Volume in the First Second (FEV1)0.052 ± 0.0064-0.004 ± 0.0062
Statistical analysis
  • Roflumilast 500 µg vs Placebo · ANCOVA · p = <0.0001 · Ls mean difference: 0.056 · 95% CI 0.038 to 0.073Analysis of Covariance (ANCOVA) including treatment by time interaction.
SecondaryRate of Severe COPD Exacerbations Per Patient Per Year

A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient's baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management. Severe COPD exacerbations were categorized as requiring hospitalization and/or leading to death. The defined number of days a patient was in the trial was divided by 365.25, in order to express the duration as a fraction of 1 year.

Time frame:
52 weeks
Reported as:
Mean · exacerbations per patient per year
Rate of Severe COPD Exacerbations Per Patient Per Year
exacerbations per patient per yearRoflumilast 500 µgPlacebo
Rate of Severe COPD Exacerbations Per Patient Per Year0.239 (0.201 to 0.283)0.315 (0.270 to 0.368)
Statistical analysis
  • Roflumilast 500 µg vs Placebo · Generalized Linear Regression · p = 0.0175 · Rate ratio: 0.757 · 95% CI 0.601 to 0.952A rate ratio of \< 1 represents a favourable outcome for the test treatment.
SecondaryRate of COPD Exacerbations Per Patient Per Year All Categories

A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient's baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management. COPD exacerbations were categorized as follows: Severe=Requiring hospitalization and/or leading to death; Moderate=Requiring oral or parenteral glucocorticosteroid therapy. The defined number of days a patient was in the trial was divided by 365.25, in order to express the duration as a fraction of 1 year.

Time frame:
52 weeks
Reported as:
Mean · exacerbations per patient per year
Rate of COPD Exacerbations Per Patient Per Year All Categories
exacerbations per patient per yearRoflumilast 500 µgPlacebo
Moderate0.574 (0.508 to 0.648)0.627 (0.561 to 0.702)
Mild, Moderate or Severe3.078 (2.723 to 3.479)3.879 (3.492 to 4.310)
Leading to Hospitalisation0.238 (0.200 to 0.283)0.313 (0.268 to 0.365)
Glucocorticosteroids and/or Antibiotics treatment0.794 (0.716 to 0.88)0.929 (0.847 to 1.019)
Moderate or Severe and/or treated with Antibiotics1.012 (0.922 to 1.110)1.210 (1.115 to 1.313)
Statistical analysis
  • Roflumilast 500 µg vs Placebo · Generalized Linear Regression · p = 0.2875 (Level of significance: 5% 2-sided) · Rate ratio: 0.914 · 95% CI 0.775 to 1.078A rate ratio of \< 1 represents a favourable outcome for the test treatment.
  • Roflumilast 500 µg vs Placebo · Generalized Linear Regression · p = 0.0050 (Level of significance: 5% 2-sided) · Rate ratio: 0.794 · 95% CI 0.675 to 0.933A rate ratio of \< 1 represents a favourable outcome for the test treatment.
  • Roflumilast 500 µg vs Placebo · Generalized Linear Regression · p = 0.0262 (Level of significance: 5% 2-sided) · Rate ratio: 0.854 · 95% CI 0.744 to 0.982A rate ratio of \< 1 represents a favourable outcome for the test treatment.
  • Roflumilast 500 µg vs Placebo · Generalized Linear Regression · p = 0.0047 (Level of significance: 5% 2-sided) · Rate ratio: 0.837 · 95% CI 0.739 to 0.947A rate ratio of \< 1 represents a favourable outcome for the test treatment.
  • Roflumilast 500 µg vs Placebo · Generalized Linear Regression · p = 0.0209 (Level of significance: 5% 2-sided.) · Rate ratio: 0.761 · 95% CI 0.604 to 0.960A rate ratio of \< 1 represents a favourable outcome for the test treatment.
SecondaryPercentage of Participants Experiencing at Least 1 COPD Exacerbation

A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient's baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management.

Time frame:
52 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing at Least 1 COPD Exacerbation
percentage of participantsRoflumilast 500 µgPlacebo
Percentage of Participants Experiencing at Least 1 COPD Exacerbation55.260.5
SecondaryTime to First COPD Exacerbation All Categories

Time to event was calculated as date of onset of event - date of first intake of double-blind study drug + 1 day for all events: mild, moderate or severe. A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient's baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management.

Time frame:
52 Weeks
Reported as:
Median · days
Time to First COPD Exacerbation All Categories
daysRoflumilast 500 µgPlacebo
Time to First COPD Exacerbation All Categories218.0 (189.0 to 259.0)180.0 (147.0 to 200.0)
Statistical analysis
  • Roflumilast 500 µg vs Placebo · Cox proportional hazards model · p = 0.1461 (Level of significance: 5% 2-sided.) · Hazard ratio (hr): 0.917 · 95% CI 0.815 to 1.031A hazards ratio of \< 1 represents a lower hazard for the test treatment.
SecondaryTime to Second Moderate or Severe COPD Exacerbation

Time to event was calculated as date of onset of event - date of first intake of double-blind study drug + 1 day for events: moderate or severe. A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient's baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management. COPD exacerbations were categorized as Severe: Requiring hospitalization and/or leading to death; Moderate: Requiring oral or parenteral glucocorticosteroid therapy.

Time frame:
52 Weeks (some participants extended treatment beyond 52 Weeks and are included in the analysis)
Reported as:
Median · days
Time to Second Moderate or Severe COPD Exacerbation
daysRoflumilast 500 µgPlacebo
Time to Second Moderate or Severe COPD Exacerbation421.0 (413.0 to NA)NA (NA to NA)
Statistical analysis
  • Roflumilast 500 µg vs Placebo · Wei-Lin-Weissfeld Method · p = 0.0270 (Level of significance: 5% 2-sided) · Hazard ratio (hr): 0.790 · 95% CI 0.641 to 0.974A hazard ratio of \<1 represents a favourable outcome for the test treatment
SecondaryTime to Third Moderate or Severe COPD Exacerbation

Time to event was calculated as date of onset of event - date of first intake of double-blind study drug + 1 day for events: moderate or severe. A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient's baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management. COPD exacerbations were categorized as Severe: Requiring hospitalization and/or leading to death; Moderate: Requiring oral or parenteral glucocorticosteroid therapy.

Time frame:
52 Weeks
Reported as:
Median · days
Time to Third Moderate or Severe COPD Exacerbation
daysRoflumilast 500 µgPlacebo
Time to Third Moderate or Severe COPD ExacerbationNA (NA to NA)NA (NA to NA)
Statistical analysis
  • Roflumilast 500 µg vs Placebo · Wei-Lin-Weissfeld Method · p = 0.0731 (Level of significance: 5% 2-sided) · Hazard ratio (hr): 0.749 · 95% CI 0.546 to 1.027A hazard ratio of \<1 represents a favourable outcome for the test treatment.
SecondaryNumber of Patients Needed to Treat to Avoid 1 Moderate or Severe COPD Exacerbation Derived From Exacerbation Per Patient Per Year

The number needed to treat (NNT) analysis is a simple, concise method to quantify directly the benefits that alternative treatment options have on disease outcomes in terms of the number of patients who need to be treated before a benefit is observed. Risk reduction: Rate(Placebo)- Rate (Roflumilast 500 μg), Number needed to treat for benefit (NNTB): 1/(Risk reduction). A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient's baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management. COPD exacerbations were categorized as Severe: Requiring hospitalization and/or leading to death; Moderate: Requiring oral or parenteral glucocorticosteroid therapy.

Time frame:
52 Weeks
Reported as:
Number · participants
Number of Patients Needed to Treat to Avoid 1 Moderate or Severe COPD Exacerbation Derived From Exacerbation Per Patient Per Year
participantsRoflumilast 500 µgPlacebo
Number of Patients Needed to Treat to Avoid 1 Moderate or Severe COPD Exacerbation Derived From Exacerbation Per Patient Per Year0.8050.927
Statistical analysis
  • Roflumilast 500 µg vs Placebo · Nntb: 9 · 95% CI 4 to 31
SecondaryNumber of Moderate or Severe COPD Exacerbation Days

A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient's baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management. The number of exacerbation days per patient is the sum of durations (stop date of exacerbation - start date of exacerbation + 1) of all exacerbations within the category.

Time frame:
52 Weeks
Reported as:
Mean · days
Number of Moderate or Severe COPD Exacerbation Days
daysRoflumilast 500 µgPlacebo
Number of Moderate or Severe COPD Exacerbation Days26.9 ± 23.0930.9 ± 29.49
SecondaryDuration of Moderate or Severe COPD Exacerbations Per Participant

A COPD exacerbation is an event in the natural course of the disease characterized by a worsening in the patient's baseline dyspnoea, cough, and/or sputum production beyond day to day variability sufficient to warrant a change in management.

Time frame:
52 Weeks
Reported as:
Mean · days
Duration of Moderate or Severe COPD Exacerbations Per Participant
daysRoflumilast 500 µgPlacebo
Duration of Moderate or Severe COPD Exacerbations Per Participant15.9 ± 10.5916.6 ± 14.49
SecondaryChange From Baseline in Post-Bronchodilator Forced Vital Capacity (FVC)

Forced vital capacity is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Least-squares means was from ANCOVA including treatment by time interaction. A positive change from Baseline indicates improvement.

Time frame:
52 weeks
Reported as:
Least squares mean · liters
Change From Baseline in Post-Bronchodilator Forced Vital Capacity (FVC)
litersRoflumilast 500 µgPlacebo
Change From Baseline in Post-Bronchodilator Forced Vital Capacity (FVC)0.036 ± 0.0114-0.057 ± 0.0111
Statistical analysis
  • Roflumilast 500 µg vs Placebo · Repeated measurement model · p = <0.0001 (Level of significance: 5% 2-sided.) · Least square mean difference: 0.092 · 95% CI 0.061 to 0.124Unstructured covariance structure and restricted maximum likelihood (REML).
SecondaryChange From Baseline in Post-Bronchodilator Forced Expiratory Flow at 25% to 75% of Vital Capacity (FEF25-75%)

Forced expiratory flow 25-75% (FEF25-75%) is the flow (or speed) of air coming out of the lung during the middle half of a forced expiration. Pulmonary function testing was performed using centralized spirometry. Least-squares means was from ANCOVA including treatment by time interaction. A positive change from Baseline indicates improvement.

Time frame:
52 weeks
Reported as:
Least squares mean · liters/second
Change From Baseline in Post-Bronchodilator Forced Expiratory Flow at 25% to 75% of Vital Capacity (FEF25-75%)
liters/secondRoflumilast 500 µgPlacebo
Change From Baseline in Post-Bronchodilator Forced Expiratory Flow at 25% to 75% of Vital Capacity (FEF25-75%)0.035 ± 0.00440.009 ± 0.0043
Statistical analysis
  • Roflumilast 500 µg vs Placebo · Repeated measurement model · p = <0.0001 (Level of significance: 5% 2-sided.) · Least square mean difference: 0.025 · 95% CI 0.013 to 0.038Unstructured covariance structure and REML.
SecondaryChange From Baseline in Post-Bronchodilator Forced Expiratory Volume in the First 6 Seconds (FEV6)

FEV6 is the amount of air which can be forcibly exhaled from the lungs in the first six seconds of a forced exhalation. Pulmonary function testing was performed using centralized spirometry. A positive change from Baseline indicates improvement.

Time frame:
52 weeks
Reported as:
Least squares mean · liters
Change From Baseline in Post-Bronchodilator Forced Expiratory Volume in the First 6 Seconds (FEV6)
litersRoflumilast 500 µgPlacebo
Change From Baseline in Post-Bronchodilator Forced Expiratory Volume in the First 6 Seconds (FEV6)0.061 ± 0.0093-0.033 ± 0.0091
Statistical analysis
  • Roflumilast 500 µg vs Placebo · Repeated measurement model · p = <0.0001 (Level of significance: 5% 2-sided.) · Least square mean difference: 0.094 · 95% CI 0.069 to 0.120Unstructured covariance structure and REML.
SecondaryChange From Baseline in Post-Bronchodilator FEV1/FVC

The FEV1/FVC ratio represents the percentage of vital capacity expelled from the lungs during the first second of a forced exhalation. Pulmonary function testing was performed using centralized spirometry. A positive change from Baseline indicates improvement.

Time frame:
52 weeks
Reported as:
Mean · percent
Change From Baseline in Post-Bronchodilator FEV1/FVC
percentRoflumilast 500 µgPlacebo
Change From Baseline in Post-Bronchodilator FEV1/FVC1.170 ± 7.03390.580 ± 6.8405
SecondaryChange From Baseline in Use of Rescue Medication From Daily Diary

Salbutamol metered dose inhaler was available as rescue medication during the study. The participant recorded the use of rescue medication in a daily diary. A negative change from Baseline indicates an improvement.

Time frame:
Baseline and Week 52
Reported as:
Least squares mean · puffs per day
Change From Baseline in Use of Rescue Medication From Daily Diary
puffs per dayRoflumilast 500 µgPlacebo
Change From Baseline in Use of Rescue Medication From Daily Diary-0.109 ± 0.06760.173 ± 0.0654
Statistical analysis
  • Roflumilast 500 µg vs Placebo · Repeated measurement model · p = 0.0027 (Level of significance: 5% 2-sided.) · Least square mean difference: -0.283 · 95% CI -0.467 to -0.098Compound symmetry covariance structure and REML.
SecondaryChange From Baseline in COPD Symptom Score From Daily Diary

Participants recorded COPD symptoms cough and sputum production in a daily diary. Cough was assessed using a 4-point scale where 0=No cough to 3=severe cough and sputum was assessed using a 4-point scale where 0=no sputum production to 3=severe sputum production. Least-squares means from ANCOVA including treatment by time interaction. A negative change from Baseline indicates improvement. Total symptom score is the sum of cough and sputum scores, ranging from 0 (best possible outcome) to 6 (worst possible outcome).

Time frame:
52 weeks
Reported as:
Least squares mean · score on a scale
Change From Baseline in COPD Symptom Score From Daily Diary
score on a scaleRoflumilast 500 µgPlacebo
Change From Baseline in COPD Symptom Score From Daily Diary-0.412 ± 0.0315-0.398 ± 0.0306
Statistical analysis
  • Roflumilast 500 µg vs Placebo · Repeated measurement model · p = 0.7392 (Level of significance: 5% 2-sided.) · Least square mean difference: -0.015 · 95% CI -0.101 to 0.071Compound symmetry covariance structure and REML.
SecondaryPercentage of Symptom-Free Days

Symptoms of COPD (cough, sputum) were recorded in a daily diary. The percentage of days without symptoms is reported.

Time frame:
52 Weeks
Reported as:
Mean · percentage of days
Percentage of Symptom-Free Days
percentage of daysRoflumilast 500 µgPlacebo
Percentage of Symptom-Free Days7.09 ± 17.1196.88 ± 16.185
SecondaryPercentage of Rescue Medication-Free Days

Participants recorded their use of rescue medication in a daily diary. The percentage of days without rescue medication use.

Time frame:
52 Weeks
Reported as:
Mean · percentage of days
Percentage of Rescue Medication-Free Days
percentage of daysRoflumilast 500 µgPlacebo
Percentage of Rescue Medication-Free Days23.25 ± 33.73422.77 ± 33.141
SecondaryChange From Baseline in COPD Assessment Test (CAT) Total Score

Participants completed the CAT questionnaire at Baseline and after 52 Weeks of Treatment. The CAT questionnaire measures the impact of COPD on wellbeing and daily life. Participants answer 8 questions on a scale from 0 (best) to 5 (worst). The total score ranges from 0 to 40 with higher scores indicating more impact. A negative change from Baseline indicates improvement. Least-squares means from ANCOVA including treatment by time interaction.

Time frame:
Baseline and Week 52
Reported as:
Mean · score on a scale
Change From Baseline in COPD Assessment Test (CAT) Total Score
score on a scaleRoflumilast 500 µgPlacebo
Change From Baseline in COPD Assessment Test (CAT) Total Score-1.270 ± 0.1556-0.985 ± 0.1518
Statistical analysis
  • Roflumilast 500 µg vs Placebo · Repeated measurement model · p = 0.1909 (Level of significance: 5% 2-sided.) · Least square mean difference: -0.285 · 95% CI -0.711 to 0.142Unstructured covariance structure and REML.
SecondaryPercentage of Participants With Improvement in CAT

Participants completed the CAT questionnaire at Baseline and after 52 Weeks of treatment. The CAT questionnaire measures the impact of COPD on wellbeing and daily life. Participants answer 8 questions on a scale from 0 (best) to 5 (worst). The total score ranges from 0 to 40 with higher scores indicating more impact. Improvement was defined as a CAT Total Score reduction from Baseline \> 1.6.

Time frame:
Baseline and Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With Improvement in CAT
percentage of participantsRoflumilast 500 µgPlacebo
Percentage of Participants With Improvement in CAT71.272.5
SecondaryTime to Mortality Due to Any Reason During the Treatment Period Score

Time to event will be calculated as date of onset of event - date of first intake of double-blind study drug + 1 day.

Time frame:
52 Weeks (some participants extended treatment beyond 52 Weeks and are included in the analysis)
Reported as:
Median · days
Time to Mortality Due to Any Reason During the Treatment Period Score
daysRoflumilast 500 µgPlacebo
Time to Mortality Due to Any Reason During the Treatment Period ScoreNA (44 to 381)NA (21 to 293)
Statistical analysis
  • Roflumilast 500 µg vs Placebo · Cox-proportional hazards model · p = 0.9414 (Level of significance: 5% 2-sided.) · Hazard ratio (hr): 1.025 · 95% CI 0.528 to 1.990A hazards ratio of \< 1 represents a lower hazard for the test treatment.
SecondaryTime to Mortality Due to COPD Exacerbation During the Treatment Period

Time to event will be calculated as date of onset of event - date of first intake of double-blind study drug + 1 day.

Time frame:
52 Weeks
Reported as:
Median · days
Time to Mortality Due to COPD Exacerbation During the Treatment Period
daysRoflumilast 500 µgPlacebo
Time to Mortality Due to COPD Exacerbation During the Treatment PeriodNA (44 to 322)NA (25 to 293)
Statistical analysis
  • Roflumilast 500 µg vs Placebo · Cox-proportional hazards model · p = 0.8876 · Hazard ratio (hr): 1.078 · 95% CI 0.378 to 3.075A hazards ratio of \< 1 represents a lower hazard for the test treatment.
SecondaryTime to Withdrawal During the Treatment Period

Time to event will be calculated as date of onset of event - date of first intake of double-blind study drug + 1 day.

Time frame:
52 Weeks (some participants extended treatment beyond 52 Weeks and are included in the analysis)
Reported as:
Median · days
Time to Withdrawal During the Treatment Period
daysRoflumilast 500 µgPlacebo
Time to Withdrawal During the Treatment Period420.0 (5 to 428)444.0 (1 to 444)
Statistical analysis
  • Roflumilast 500 µg vs Placebo · Cox-proportional hazards model · p = <0.0001 · Hazard ratio (hr): 1.529 · 95% CI 1.268 to 1.845A hazards ratio of \< 1 represents a lower hazard for the test treatment.
SecondaryTime to Withdrawal Due to COPD Exacerbation During the Treatment Period

Time to event will be calculated as date of onset of event - date of first intake of double-blind study drug + 1 day.

Time frame:
52 Weeks (some participants extended treatment beyond 52 Weeks and are included in the analysis)
Reported as:
Median · days
Time to Withdrawal Due to COPD Exacerbation During the Treatment Period
daysRoflumilast 500 µgPlacebo
Time to Withdrawal Due to COPD Exacerbation During the Treatment PeriodNA (25 to 371)NA (12 to 319)
Statistical analysis
  • Roflumilast 500 µg vs Placebo · Cox-proportional hazards model · p = 0.3477 (Level of significance: 5% 2-sided.) · Hazard ratio (hr): 0.695 · 95% CI 0.326 to 1.484A hazards ratio of \< 1 represents a lower hazard for the test treatment.
SecondaryPercentage of Participants With Major Adverse Cardiovascular Event (MACE) During the Treatment Period

Composite MACE is a combined endpoint (cardiovascular death \[including death due to undetermined cause\], nonfatal myocardial infarction, and nonfatal stroke).

Time frame:
52 Weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Major Adverse Cardiovascular Event (MACE) During the Treatment Period
percentage of participantsRoflumilast 500 µgPlacebo
Percentage of Participants With Major Adverse Cardiovascular Event (MACE) During the Treatment Period1.71.7
SecondaryTime to First Major Adverse Cardiovascular Event (MACE) During the Treatment Period

Composite MACE is a combined endpoint(cardiovascular death \[including death due to undetermined cause\], nonfatal myocardial infarction, and nonfatal stroke). Time to event was calculated as date of onset of event - date of first intake of double-blind study drug + 1 day.

Time frame:
52 Weeks (some participants extended treatment beyond 52 Weeks and are included in the analysis)
Reported as:
Median · days
Time to First Major Adverse Cardiovascular Event (MACE) During the Treatment Period
daysRoflumilast 500 µgPlacebo
Time to First Major Adverse Cardiovascular Event (MACE) During the Treatment PeriodNA (52 to 415)NA (50 to 365)
Statistical analysis
  • Roflumilast 500 µg vs Placebo · Cox-proportional hazards model · p = 0.8208 (Level of significance: 5% 2-sided.) · Hazard ratio (hr): 1.083 · 95% CI 0.542 to 2.167A hazards ratio of \< 1 represents a lower hazard for the test treatment.
SecondaryPercentage of Participant With All-Cause Hospitalisation During the Treatment Period

Percentage of patients with at least one hospital admission due to any cause.

Time frame:
52 Weeks
Reported as:
Number · percentage of participants
Percentage of Participant With All-Cause Hospitalisation During the Treatment Period
percentage of participantsRoflumilast 500 µgPlacebo
Percentage of Participant With All-Cause Hospitalisation During the Treatment Period24.929.3
SecondaryTime to First Hospitalisation Due to Any Cause During the Treatment Period

Time to event will be calculated as date of onset of event - date of first intake of double-blind study drug + 1 day.

Time frame:
52 Weeks (some participants extended treatment beyond 52 Weeks and are included in the analysis)
Reported as:
Median · days
Time to First Hospitalisation Due to Any Cause During the Treatment Period
daysRoflumilast 500 µgPlacebo
Time to First Hospitalisation Due to Any Cause During the Treatment Period400.0 (387.0 to 415.0)408.0 (391.0 to 420.0)
Statistical analysis
  • Roflumilast 500 µg vs Placebo · Cox-proportional hazards model · p = 0.7943 (Level of significance: 5% 2-sided.) · Hazard ratio (hr): 0.977 · 95% CI 0.821 to 1.162
SecondaryTime to Trial Withdrawal Due to an Adverse Event

Time to event will be calculated as date of onset of event - date of first intake of double-blind study drug + 1 day.

Time frame:
52 Weeks (some participants extended treatment beyond 52 Weeks and are included in the analysis)
Reported as:
Median · days
Time to Trial Withdrawal Due to an Adverse Event
daysRoflumilast 500 µgPlacebo
Time to Trial Withdrawal Due to an Adverse EventNA (7 to 420)NA (13 to 444)
SecondaryPercentage of Participants Who Experienced at Least 1 Treatment Emergent Adverse Event (TEAE)

An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.

Time frame:
52 Weeks
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced at Least 1 Treatment Emergent Adverse Event (TEAE)
percentage of participantsRoflumilast 500 µgPlacebo
Percentage of Participants Who Experienced at Least 1 Treatment Emergent Adverse Event (TEAE)66.959.2
SecondaryChange From Baseline in Body Weight

Least Square Means was from an ANCOVA model including Last Observation Carried Forward (LOCF).

Time frame:
Baseline and Week 52
Reported as:
Least squares mean · kilogram (kg)
Change From Baseline in Body Weight
kilogram (kg)Roflumilast 500 µgPlacebo
Change From Baseline in Body Weight-2.66 ± 0.130-0.14 ± 0.130
SecondaryChange From Baseline in Body Mass Index (BMI)

Body mass index (BMI) is a measure of body fat based on height and weight. Least Square Means was from an ANCOVA model including LOCF.

Time frame:
Baseline and Week 52
Reported as:
Least squares mean · kg/m^2
Change From Baseline in Body Mass Index (BMI)
kg/m^2Roflumilast 500 µgPlacebo
Change From Baseline in Body Mass Index (BMI)-0.94 ± 0.046-0.04 ± 0.046

Adverse events

Collected over 52 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Roflumilast 500 µg—249/968 (25.7%)228/968 (23.6%)
Placebo—285/967 (29.5%)114/967 (11.8%)
Most frequent serious events
Showing 10 of 225
Most frequent serious events
EventRoflumilast 500 µgPlacebo
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders144/968184/967
PneumoniaInfections and infestations33/96837/967
Infective exacerbation of chronic obstructive airways diseaseInfections and infestations3/9687/967
Atrial fibrillationCardiac disorders6/9686/967
Angina pectorisCardiac disorders1/9685/967
Cardiac failureCardiac disorders3/9685/967
Myocardial infarctionCardiac disorders3/9685/967
PneumothoraxRespiratory, thoracic and mediastinal disorders5/9681/967
Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/9684/967
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)4/9684/967
Most frequent other events
Most frequent other events
EventRoflumilast 500 µgPlacebo
DiarrhoeaGastrointestinal disorders97/96833/967
Weight decreasedInvestigations84/96827/967
NauseaGastrointestinal disorders55/96815/967
NasopharyngitisInfections and infestations52/96852/967

Baseline characteristics

Full Analysis Set (FAS) includes all randomised participants who took at least 1 dose of investigational medicinal product (IMP) after randomisation.

Age, Continuous
Age, Continuous(years)Roflumilast 500 µgPlaceboTotal
Mean64.7 ± 8.3864.7 ± 8.3764.7 ± 8.37
Age, Customized
Age, Customized(participants)Roflumilast 500 µgPlaceboTotal
≤ 65 years5275421069
> 65 years442424866
Gender
Gender(Participants)Roflumilast 500 µgPlaceboTotal
Female251241492
Male7187251443
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Roflumilast 500 µgPlaceboTotal
Asian201636
Black or African American6511
White9409431883
Other325
Region of Enrollment
Region of Enrollment(participants)Roflumilast 500 µgPlaceboTotal
Australia91625
Austria11314
Belgium191837
Brazil423880
Canada141226
Denmark151934
France161329
Germany7063133
Greece383068
Hungary111125236
Israel114126240
Italy6451115
Korea, Republic Of11718
Netherlands11819
Poland8888176
Russian Federation177181358
Slovakia253358
South Africa233053
Spain373370
Turkey524496
United Kingdom222850
Height
Height(cm)Roflumilast 500 µgPlaceboTotal
Mean168.20 ± 8.652168.33 ± 8.198168.26 ± 8.427
Weight
Weight(kg)Roflumilast 500 µgPlaceboTotal
Mean75.07 ± 17.27575.60 ± 17.23875.33 ± 17.254
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Roflumilast 500 µgPlaceboTotal
Mean26.45 ± 5.47426.58 ± 5.35926.52 ± 5.416

12 further baseline measures are reported on the registry.

08

Study locations

180 sites
  • Nycomed Investigational Site
    Box Hill, 3128, Australia
  • Nycomed Investigational Site
    Clayton, 3168, Australia
  • Nycomed Investigational Site
    Concord, 2139, Australia
  • Nycomed Investigational site
    Daws Park, 5041, Australia
  • Nycomed Investigational Site
    Frankston, 3199, Australia
  • Nycomed Investigational Site
    Heidelberg, 3084, Australia
  • Nycomed Investigational Site
    Parkville, 3050, Australia
  • Nycomed Investigational Site
    Toorak Gardens, 5065, Australia
  • Nycomed Investigational Site
    Feldbach, 8330, Austria
  • Nycomed Investigational Site
    Graz, 8036, Austria
  • Nycomed Investigational Site
    Salzburg, 5020, Austria
  • Nycomed Investigational Site
    Wien, 1140, Austria
  • Nycomed Investigational Site
    Bruxelles, 1000, Belgium
  • Nycomed Investigational Site
    Bruxelles, 1200, Belgium
  • Nycomed Investigational Site
    Halen, 3545, Belgium
  • Nycomed Investigational Site
    Liege, 4000, Belgium
  • Nycomed Investigational Site
    Malmedy, 4960, Belgium
  • Nycomed Investigational Site
    Belo Horizonte, Brazil
  • Nycomed Investigational Site
    Botucatu, Brazil
  • Nycomed Investigational Site
    Florianópolis, Brazil
  • Nycomed Investigational Site
    Goiânia, Brazil
  • Nycomed Investigational Site
    Porto Alegre, Brazil
  • Nycomed Investigational Site
    Rio de Janeiro, Brazil
  • Nycomed Investigational Site
    Sao Paolo, Brazil
  • Nycomed Investigational Site
    Vitória, Brazil
  • Nycomed Investigational Site
    Hamilton, L8N 4A6, Canada
  • Nycomed Investigational Site
    Kingston, K7L 2V7, Canada
  • Nycomed Investigational Site
    Lachine, H8S 2E4, Canada
  • Nycomed Investigational Site
    Niagara Falls, L2G 1J4, Canada
  • Nycomed Investigational Site
    Richmond Hill, L4C 2N9, Canada
  • Nycomed Investigational Site
    Toronto, M5T 3A9, Canada
  • Nycomed Investigational Site
    Toronto, M6H 3M2, Canada
  • Nycomed Investigational Site
    Winnepeg, R2K 3S8, Canada
  • Nycomed Investigational Site
    Hellerup, 2900, Denmark
  • Nycomed Investigational Site
    Hillerød, 3400, Denmark
  • Nycomed Investigational Site
    Hvidovre, 2650, Denmark
  • Nycomed Investigational Site
    København NV, 2400, Denmark
  • Nycomed Investigational Site
    Férolles Attilly, 77150, France
  • Nycomed Investigational Site
    Nîmes, 30900, France
  • Nycomed Investigational Site
    Poitiers, 86021, France
  • Nycomed Investigational Site
    Saint-Laurent du Var, 06700, France
  • Nycomed Investigational Site
    Strasbourg, 67091, France
  • Nycomed Investigational Site
    Berlin, 10367, Germany
  • Nycomed Investigational Site
    Berlin, 10969, Germany
  • Nycomed Investigational Site
    Berlin, 12203, Germany
  • Nycomed Investigational Site
    Fürth, 90766, Germany
  • Nycomed Investigational Site
    Großhansdorf, 22927, Germany
  • Nycomed Investigational Site
    Hannover, 30167, Germany
  • Nycomed Investigational Site
    Homburg, 66421, Germany
  • Nycomed Investigational Site
    Koblenz, 56068, Germany
  • Nycomed Investigational Site
    Marburg, 35043, Germany
  • Nycomed Investigational Site
    Rüdersdorf, 15562, Germany
  • Nycomed Investigational Site
    Alexandroupolis, 68100, Greece
  • Nycomed Investigational Site
    Athens, 10676, Greece
  • Nycomed Investigational Site
    Athens, 11527, Greece
  • Nycomed Investigational Site
    Heraklion, Crete, 71110, Greece
  • Nycomed Investigational Site
    Kavala, 65201, Greece
  • Nycomed Investigational Site
    Larissa, 41100, Greece
  • Nycomed Investigational Site
    Marousi, 15126, Greece
  • Nycomed Investigational Site
    Thessaloniki, 57010, Greece
  • Nycomed Investigational Site
    Balassagyarmat, 2660, Hungary
  • Nycomed Investigational Site
    Budapest, 1125, Hungary
  • Nycomed Investigational Site
    Cegléd, 2700, Hungary
  • Nycomed Investigational Site
    Csorna, 9300, Hungary
  • Nycomed Investigational Site
    Deszk, 6772, Hungary
  • Nycomed Investigational Site
    Erd, Hungary
  • Nycomed Investigational Site
    Miskolc, 3526, Hungary
  • Nycomed Investigational Site
    Nyíregyháza, 4400, Hungary
  • Nycomed Investigational Site
    Pécs, 7623, Hungary
  • Nycomed Investigational Site
    Siófok, 8600, Hungary
  • Nycomed Investigational Site
    Sopron, 9400, Hungary
  • Nycomed Investigational Site
    Szombathely, 9700, Hungary
  • Nycomed Investigational Site
    Törökbálint, 2045, Hungary
  • Nycomed Investigational Site
    Ashkelon, 78278, Israel
  • Nycomed Investigational Site
    Beer Sheva, 84101, Israel
  • Nycomed Investigational Site
    Haifa, 31096, Israel
  • Nycomed Investigational Site
    Haifa, 34362, Israel
  • Nycomed Investigational Site
    Holon, 58100, Israel
  • Nycomed Investigational Site
    Jerusalem, 91031, Israel
  • Nycomed Investigational Site
    Jerusalm, 91120, Israel
  • Nycomed Investigational Site
    Kfar Saba, 44281, Israel
  • Nycomed Investigational Site
    Petach Tikva, 49100, Israel
  • Nycomed Investigational Site
    Rehovot, 76100, Israel
  • Nycomed Investigational Site
    Tel Aviv, 67891, Israel
  • Nycomed Investigational Site
    Tel Hashomer, 52621, Israel
  • Nycomed Investigational Site
    Tel-Aviv, 64239, Israel
  • Nycomed Investigational Site
    Ferrara, 44011, Italy
  • Nycomed Investigational Site
    Genova, 16132, Italy
  • Nycomed Investigational Site
    Milano, 20122, Italy
  • Nycomed Investigational Site
    Milano, 20138, Italy
  • Nycomed Investigational Site
    Modena, 41100, Italy
  • Nycomed Investigational Site
    Monza, 20052, Italy
  • Nycomed Investigational Site
    Pordenone, 33170, Italy
  • Nycomed Investigational Site
    Roma, 00133, Italy
  • Nycomed Investigational Site
    Anyang, 431-070, Korea, Republic of
  • Nycomed Investigational Site
    Cheongju, 361-711, Korea, Republic of
  • Nycomed Investigational Site
    Daegu, Korea, Republic of
  • Nycomed Investigational Site
    Seoul, 110-744, Korea, Republic of
  • Nycomed Investigational Site
    Seoul, 120-752, Korea, Republic of
  • Nycomed Investigational Site
    Seoul, 152-703, Korea, Republic of

Showing the first 100 of 180 sites across 21 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Facius A, Marostica E, Gardiner P, Watz H, Lahu G. Pharmacokinetic and Pharmacodynamic Modelling to Characterize the Tolerability of Alternative Up-Titration Regimens of Roflumilast in Patients with Chronic Obstructive Pulmonary Disease. Clin Pharmacokinet. 2018 Aug;57(8):1029-1038. doi: 10.1007/s40262-018-0671-4. PubMed 29797235 ↗
  • Martinez FJ, Rabe KF, Calverley PMA, Fabbri LM, Sethi S, Pizzichini E, McIvor A, Anzueto A, Alagappan VKT, Siddiqui S, Reisner C, Zetterstrand S, Roman J, Purkayastha D, Bagul N, Rennard SI. Determinants of Response to Roflumilast in Severe Chronic Obstructive Pulmonary Disease. Pooled Analysis of Two Randomized Trials. Am J Respir Crit Care Med. 2018 Nov 15;198(10):1268-1278. doi: 10.1164/rccm.201712-2493OC. PubMed 29763572 ↗
  • Rabe KF, Calverley PMA, Martinez FJ, Fabbri LM. Effect of roflumilast in patients with severe COPD and a history of hospitalisation. Eur Respir J. 2017 Jul 5;50(1):1700158. doi: 10.1183/13993003.00158-2017. Print 2017 Jul. No abstract available. PubMed 28679611 ↗
  • Martinez FJ, Calverley PM, Goehring UM, Brose M, Fabbri LM, Rabe KF. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet. 2015 Mar 7;385(9971):857-66. doi: 10.1016/S0140-6736(14)62410-7. Epub 2015 Feb 13. PubMed 25684586 ↗
  • Calverley PM, Martinez FJ, Fabbri LM, Goehring UM, Rabe KF. Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocol. Int J Chron Obstruct Pulmon Dis. 2012;7:375-82. doi: 10.2147/COPD.S31100. Epub 2012 Jun 20. PubMed 22791991 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2011, a primary completion of Mar 2014 and a completion of May 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2015, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2011
First posted
Apr 5, 2011
Start
May 2011
Primary completionActual
Mar 2014
CompletionActual
May 2014
Results first posted
Oct 29, 2015
Last update
Dec 13, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 13, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01329029
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Apr 5, 2011
Start date
May 2011
Primary completion
Mar 2014
Completion
May 2014
Results posted
Oct 29, 2015
Last update
Dec 13, 2016

Study contacts

AstraZeneca AstraZeneca
study director · AstraZeneca

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Roflumilast

Start the discussion